Flowvium
Volver al Explorador

AbbVie Inc.

ABBVleader

AbbVie is a global biopharmaceutical company that was spun off from Abbott Laboratories in 2013. While Humira was once the world's best-selling drug, AbbVie has successfully navigated its patent cliff with Skyrizi and Rinvoq, which are on track to exceed Humira's peak revenue combined.

Compartir:
⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($56.3B)

Datos estáticos (cargando finanzas en tiempo real…)

Immunology (45%)
Aesthetics/Neuroscience (25%)
Oncology (15%)
Eye Care & Other (15%)

Composición de segmentos y clientes principales

Detalles del producto

Skyrizi / Rinvoq35%

Next-generation immunology biologics replacing Humira revenue

Humira20%

Anti-TNF biologic for rheumatoid arthritis and autoimmune diseases (declining post-LOE)

Botox / Aesthetics25%

Allergan aesthetics portfolio including Botox, Juvederm, and CoolSculpting

Relaciones en la Cadena de Suministro

Competidores

Eli Lilly and Company

Immunology and oncology drugs

Impacto: Key therapeutic competitor

Regeneron Pharmaceuticals

Dupixent vs Skyrizi/Rinvoq

Impacto: Direct immunology competition

Pfizer Inc.

Broad pharmaceutical portfolio overlap

Impacto: Major pharma rival

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Señales Institucionales

InstituciónAcciónValorTrimestreFecha de presentación
BlackRockaccumulating$717M2024.062024-08-13↑
BlackRockreducing$272M2024.062024-08-13↓
BlackRockreducing$277M2024.062024-08-13↓
BlackRockreducing$21M2024.062024-08-13↓
BlackRockreducing$43M2024.062024-08-13↓
BlackRockaccumulating$507M2024.062024-08-13↑
BlackRockaccumulating$571M2024.062024-08-13↑
BlackRockaccumulating$8.8B2024.062024-08-13↑
BlackRockaccumulating$6.6B2024.062024-08-13↑
BlackRockaccumulating$563M2024.062024-08-13↑
BlackRockaccumulating$923M2024.062024-08-13↑
BlackRockreducing$346M2024.062024-08-13↓
BlackRockaccumulating$608M2024.062024-08-13↑
BlackRockreducing$6M2024.062024-08-13↓
BlackRockaccumulating$1.9B2024.062024-08-13↑
BlackRockreducing$83M2024.062024-08-13↓
BlackRockreducing$30M2024.062024-08-13↓
BlackRockaccumulating$643M2024.062024-08-13↑
BlackRockreducing$64M2024.062024-08-13↓
BlackRockreducing$11M2024.062024-08-13↓
BlackRockreducing$15M2024.062024-08-13↓
BlackRockreducing$399K2024.062024-08-13↓
BlackRockaccumulating$460M2024.062024-08-13↑
Vanguard Groupaccumulating$2.3B2025.122026-01-29↑
Vanguard Groupaccumulating$193M2025.122026-01-29↑
Vanguard Groupaccumulating$37.1B2025.122026-01-29↑
Vanguard Groupaccumulating$754M2025.122026-01-29↑
Vanguard Groupaccumulating$882M2025.122026-01-29↑
Vanguard Groupaccumulating$9M2025.122026-01-29↑
State Streetaccumulating$18.5B2025.122026-02-13↑
Wellington Managementaccumulating$3.1B2025.122026-02-17↑
Wellington Managementaccumulating$65M2025.122026-02-17↑
Wellington Managementreducing$32M2025.122026-02-17↓
Wellington Managementreducing$46M2025.122026-02-17↓
Wellington Managementreducing$24M2025.122026-02-17↓
Wellington Managementreducing$42M2025.122026-02-17↓
Wellington Managementreducing$37M2025.122026-02-17↓
Wellington Managementreducing$5M2025.122026-02-17↓
Wellington Managementaccumulating$93M2025.122026-02-17↑
FMR (Fidelity)accumulating$3.8B2025.122026-02-17↑
FMR (Fidelity)accumulating$280M2025.122026-02-17↑
FMR (Fidelity)accumulating$822M2025.122026-02-17↑
FMR (Fidelity)accumulating$41M2025.122026-02-17↑
FMR (Fidelity)accumulating$218M2025.122026-02-17↑
FMR (Fidelity)accumulating$25M2025.122026-02-17↑

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de AbbVie Inc. impulsado por IA.

Información de la Empresa

Sede Central

North Chicago, Illinois, USA

Fundación

2013

Empleados

50,000+

Sitio Web

abbvie.com

Estado del sector — 제약 / 바이오

Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Temas clave

  • •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
  • •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
  • •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성

Próximos catalizadores

  • ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
  • ◆MRNA 암백신 FDA BLA 제출 예정